诺诚健华奥布替尼20多项研究数据亮相第67届美国血液学会（ASH）年会

Core Viewpoint - The biopharmaceutical company, Nuo Cheng Jian Hua, announced the presentation of over 20 research data on its novel BTK inhibitor, Oubatinib, at the 67th American Society of Hematology (ASH) annual meeting, showcasing its efficacy and safety across various lymphoma studies. Group 1: Efficacy and Safety Data - Oubatinib demonstrated a total response rate (ORR) of 89.5% and a complete response rate (CRR) of 78.9% after six treatment cycles, with a median time to response of 2.6 months and a 2-year duration of response (DoR) of 72.4% [2] - In a study involving newly diagnosed primary central nervous system lymphoma (PCNSL), Oubatinib combined with rituximab and high-dose methotrexate showed superior predictive and prognostic value compared to PET-CT, with early clearance of ctDNA and MYD88 [1] - The combination of Oubatinib and Obinutuzumab for initial treatment of marginal zone lymphoma (MZL) showed an ORR of 96.0% and a CRR of 72.0% in 27 evaluable patients, with 100% ORR in 10 patients completing six cycles [3] - Oubatinib combined with rituximab in treatment-naïve MZL patients showed an ORR of 81.8% and a CRR of 72.7%, indicating promising efficacy despite small sample size [4] - Oubatinib combined with bendamustine-rituximab demonstrated favorable tumor response and survival outcomes compared to bendamustine-rituximab alone in high-risk mantle cell lymphoma (MCL) patients [5] Group 2: Real-World Studies and Future Research - A large-scale real-world study provided insights into treatment patterns and outcomes for different genetic subtypes of diffuse large B-cell lymphoma (DLBCL) in China, showing enhanced efficacy of R-CHOP plus BTK inhibitors in MCD-like subtype patients [6] - In the MCD-like treatment group, the CRR for R-CHOP combined with Oubatinib was 81.4% [7] - A prospective study indicated that the combination of pomalidomide, rituximab, and Oubatinib is a potential treatment option for elderly or frail DLBCL patients, achieving a 100% ORR in patients completing three cycles [7] - Oubatinib monotherapy for chronic lymphocytic leukemia (CLL) patients showed a 100% ORR and disease control rate (DCR) in both first-line and subsequent treatments [8] - Additional studies on Oubatinib are set to be presented at the 2025 ASH annual meeting, covering various combinations and treatment strategies for different lymphoma types [8]